Natriuretic peptides: Biochemistry, physiology, and therapeutic role in heart failure

Heart Disease

Volumn 5, Issue 3, 2003, Pages 215-223

  Stoupakis, George ^a   Klapholz, Marc ^b,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c Heart Failure Center   (United States)

Author keywords

Heart failure; Natriuretic peptides; Nesiritide

Indexed keywords

ANGIOTENSIN; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NEUROHORMONE; NORADRENALIN; OMAPATRILAT; VASOCONSTRICTOR AGENT; VASOPEPTIDASE INHIBITOR;

CORRELATION ANALYSIS; DISEASE SEVERITY; DIURESIS; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MOLECULAR BIOLOGY; NATRIURESIS; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; NATRIURETIC PEPTIDE, BRAIN; PROTEASE INHIBITORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038274843     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000074517.30102.64     Document Type: Review

References (92)

1. Vesely DL. Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin Exp Pharmacol Physiol. 1995;22:108-114.
2. Yasue H, Yoshimura M, Sunida H, et al. Localization and mechanism of secretion of B type natriuretic peptide in comparison with those of A type natriuretic peptide in normal subjects and those with heart failure. Circulation. 1994;90:195-203.
3. Kambayashi Y, Nakao K, Mukoyama M, et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990;259:341-345.
4. Sudoh T, Maekawa K, Kojima M, et al. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun. 1989;159:1427-1434.
5. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
6. Hunt PJ, Yandle TG, Nicholls MG, et al. The amino-terminal portion of pro-brain natriuretic peptide (Pro-bnp) circulates in human plasma. Biochem Biophys Res Commun. 1995;214:1175-1183.
7. Komatsu Y, Nakao K, Suga S, et al. C-type natriuretic peptide (CNP) in rats and humans. Endocrinology. 1991;129:1104-1106.
8. Chen H, Burnett J. C-Type natriuretic peptide: The endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998;32:S22-S28.
9. Minamino N, Kangawa K, Matsuo H. N-terminally extended form of C-type natriuretic peptide (CNP-53) identified in porcine brain. Biochem Biophys Res Commun. 1990;170:973-979.
10. Tawaragi Y, Fuchimura K, Tanaka S, et al. Gene and precursor structures of human C-type natriuretic peptide. Biochem Biophys Res Commun. 1991;175:645-651.
11. Drummer C, Kentsch M, Otter W, et al. Increased renal natriuretic peptide (urodilatin) excretion in heart failure patients. Eur J Med Res. 1997;2:347-354.
12. Koller K, Goeddel D. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992;86:1081-1088.
13. Nussenzveig D, Lewicki J, Maack T. Cellular mechanisms of the clearance function of Type C receptors of atrial natriuretic factor. J Biol Chem. 1990;265:20952-20958.
14. Fuller F, Porter JG, Arfsten AE, et al. Atrial natriuretic peptide clearance receptor. J Biol Chem. 1988;263:9395-9401.
15. Globits S, Frank H, Pacher B, et al. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J. 1998;135:592-597.
16. Edwards B, Zimmerman R, Schwab T, et al. Atrial stretch, not pressure, is the principle determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191-195.
17. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825-832.
18. Yoshimura M, Yassue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with CHF. Circulation. 1993;87:464-469.
19. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest. 1991;87:1402-1412.
20. Nazario B, Hu R, Pedram A, et al. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest. 1995;95:1151-1157.
21. Suga S-I, Nakao K, Itoh H, et al. Endothelial production of C-Type natriuretic peptide and its marked augmentation by Transforming Growth Factor-B. J Clin Invest. 1992;90:1145-1149.
22. Suga S-I, Itoh H, Komatsu Y, et al. Cytokine-induced C-Type natriuretic peptide (CNP) secretion from vascular endothelial cells-Evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993;133:3038-3041.
23. Vesely DL, Douglas MA, Dietz JR, et al. Three peptides from the atrial natriuretic factor prohormone lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994;90:1129-1140.
24. Martin DR, Pevahouse JB, Trigg DJ, et al. Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am J Physiol. 1990;258:F1401-F1408.
25. Jabs K, Zeidel M, Silva P. Prostaglandin E2 inhibits Na-K-ATPase activity in the inner medullary collecting duct. Am J Physiol. 1989;257: F424-F430.
26. Gunning ME, Brady HR, Otuechere G, et al. Atrial natriuretic peptide (31-67) inhibits Na transport in rabbit inner medullary collecting duct cells: role of prostaglandin E2. J Clin Invest. 1992;89:1411-1417.
27. Vesely DL, Bayliss JM, Sallman AL. Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Biochem Biophys Res Commun. 1987;143:186-193.
28. Green M, Ruiz OS, Kear F, et al. Dual effect of cyclic GMP on renal brush border Na-H antiporter. Proc Soc Exp Biol Med. 1991;198:846-851.
29. Mendez RE, Dunn R, Troy JL, et al. Atrial natriuretic peptide and furosemide effects on hydraulic pressure in the renal papilla. Kidney Int. 1988;34:36-42.
30. Sonnenberg H, Honrath U, Chong CK, et al. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol. 1986;250:F963-F966.
31. Denker PS, Vesely DL, Gomez-Sanchez CE. Effect of pro atrial natriuretic peptides 1-30, 31-67, and 99-126 on angiotensin II-stimulated aldosterone production in calf adrenal cells. J Ster Biochem. 1990;37:617-619.
32. Winters CJ, Sallman AL, Baker BJ, et al. The N-terminus and a 4000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation. 1989;80:438-449.
33. Ackerman BH, Wyeth RP, Vesely DL, et al. Pharmacokinetic characterization of the postdistribution phase of prohormone atrial natriuretic peptides amino acids 1-98, 31-67, and atrial natriuretic factor during and after rapid right ventricular pacing in dogs. J Clin Pharmacol. 1992;32:415-421.
34. Kambayashi Y, Nakao K, Kimura H, et al. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun. 1990;173:599-605.
35. Hunt PJ, Espiner EA, Nicholls MG, et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab. 1996;81:3871-3876.
36. Koesling D, Bohme E, Schultz G. Guanylyl cyclases, a growing family of signal-transducing enzymes. FASEB J. 1991;5:2785-2791.
37. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol. 1992;262:H308-H312.
38. Wei C, Aarhus LL, Miller VM, Burnett JC. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993;262: H71-H73.
39. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide. Endocrinology. 1992;130:229-239.
40. Furuya M, Yoshida M, Minamino N, et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177:927-931.
41. Seymour AA, Abboa-Offei BE, Smith PL, et al. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol. 1995;22:63-69.
42. Nussenzveig DR, Lewicki JA, Maack T. Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem. 1990;265:20952-20958.
43. Rademaker MT, Charles CJ, Kosoglou T, et al. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol. 1997;273(5Pt2):H2372-H2379.
44. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24. 11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996;271:R373-R380.
45. Dussaule JC, Stefanski A, Bea ML, et al. Characterization of neutral endo-peptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol. 1993;264:F45-F52.
46. Vesely D, Douglass M. Dietz J, et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab. 1994;78:1128-1134.
47. Burnett JC, Kao PC, DC HU, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
48. Wei C, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004-1009.
49. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 1986;78:1362-1374.
50. Edwards BS, Ackermann DM, Lee ME, et al. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest. 1988;81:82-86.
51. Eiskjaer H, Bagger JP, Danielsen H, et al. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol. 1991;33:61-74.
52. Levin ER, Frank HJL, Chaudhari A, et al. Decreased atrial natriuretic factor receptors and impaired cGMP generation in glomeruli form the cardiomyopathic hamster. Biochem Biophys Res Commun. 1989;159:807-814.
53. Jensen KT, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clinical Science. 1999;96:5-15.
54. Cavero PG, Margulies KB, Winaver J, et al. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 1990;82:196-201.
55. Hirooka Y, Takeshita A, lmaizumi T, et al. Attenuated forearm vasodilative response to atrial natriuretic peptide in patients with heart failure. Circulation. 1990;82:147-153.
56. Nakamura M, Arakawa N, Yoshida H, et al. Vasodilatory effects of c-Type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation. 1994;90:1210-1214.
57. Davis CL, Briggs JP. Effect ofreduction in renal artery pressure on atrial natriuretic peptide induced natriuresis. Am J Physiol. 1987;252: F146-F153.
58. Redfield MM, Edwards BS, Heublein DM, Burnett JC. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. Am J Physiol. 1989;257:R917-R923.
59. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidnev Int. 1996;50:1718-1725.
60. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829-833.
61. Clerico A, Lervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998;21:170-179.
62. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
63. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1347-1351.
64. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet. 1994;343:440-444.
65. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
66. Yamamoto K, Burnett JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-994.
67. Lubien E, De Maria A, Krishnaswamy, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation 2002;105:595-601.
68. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138:1126-1132.
69. Tsutamoto T, Wada A, Maedo K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation. 1997;96:509-516.
70. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol. 1997;47:287-296.
71. Hunt PJ, Yandle TG, Nicholls MG, et al. The amino-terminal portion of pro-brain natriuretic peptide (pro-bnp) circulates in human plasma. Biochem Biophys Res Commun. 1995;214:1175-1183.
72. Vesely DL, Dietz JR, Parks JR, et al. Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J. 1999;138:625-632.
73. Overton RM, Vesely DL. Processing of long-acting natriuretic peptide and vessel dilator in human plasma and serum. Peptides. 1996;17:1155-1162.
74. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
75. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
76. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (Human b-type natriuretic peptide) in heart failure. J Am Coll Cardiol. 1999;34:155-162.
77. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35-39.
78. Young JB, Abraham WT, Stevenson LW, et al. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
79. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
80. Frishman WH, Sica DA, Cheng JWM, et al. Natriuretic and other vasoactive peptides. In Frishman WH, Sonnenblick EH, Sica DA (eds): Cardiovascular Pharmacotherapeutics. 2nd ed. New York: McGraw Hill 2003:451-477.
81. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995;275:745-752.
82. Margulies KB, Perrella MA, McKinley LJ, Burnett JC. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest. 1991;88:1636-1642.
83. Thomas CV, McDaniel GM, Holzgrefe HH, et al. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol. 1998;32:902-912.
84. Rademaker MT, Charles CJ, Espiner EA, et al. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol. 1998;31:116-125.
85. Trippodo NC, Robl JA, Asaad MM, et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
86. Liao W, Vesterqvist O, Delaney CL, et al. Steady-state pharmacokinetics and pharmacodynamics of omapatrilat in normotensive subjects [abstract]. J Hypertens. 1996;17(Suppl 3):S66.
87. Klapholz M, Thomas I, Eng C, et al. Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol. 2001;88:657-661.
88. McClean DR, Ikram H, Garlick AH, et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:479-486.
89. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison ofvasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615-620.
90. Packer M. Omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). J Am Coll Cardiol. 2002;40:17-18.
91. th European Meeting on Hypertension, June 23-27, 2002, Prague, Czech Republic.
92. Cheng JWM. Nesiritide: review of clinical pharmacology and role in heart failure management. Heart Dis. 2002;4:199-203.